Reply
M Padberg,
M Padberg
Department of Neurology and Clinical Neurophysiology, Leyenburg Hospital, The Hague, and
Search for more papers by this author SFTM de Bruijn,
SFTM de Bruijn
Department of Neurology and Clinical Neurophysiology, Leyenburg Hospital, The Hague, and
Search for more papers by this author DLJ Tavy,
DLJ Tavy
Department of Neurology and Clinical Neurophysiology, Leyenburg Hospital, The Hague, and
Search for more papers by this author RJ de Haan,
RJ de Haan
Department of Epidemiology, Academic Medical Centre, Amsterdam, The Netherlands
Search for more papers by this author
M Padberg,
M Padberg
Department of Neurology and Clinical Neurophysiology, Leyenburg Hospital, The Hague, and
Search for more papers by this author SFTM de Bruijn,
SFTM de Bruijn
Department of Neurology and Clinical Neurophysiology, Leyenburg Hospital, The Hague, and
Search for more papers by this author DLJ Tavy,
DLJ Tavy
Department of Neurology and Clinical Neurophysiology, Leyenburg Hospital, The Hague, and
Search for more papers by this author RJ de Haan,
RJ de Haan
Department of Epidemiology, Academic Medical Centre, Amsterdam, The Netherlands
Search for more papers by this author
First published: 18 October 2005
No abstract is available for this article.
References
- 1
Ashina M,
Bendtsen L,
Jensen R,
Ekman R,
Olesen J.
Plasma levels of substance P, neuropeptide Y and vasoactive intestinal polypeptide in patients with chronic tension-type headache.
Pain
1999; 83: 541–7.
- 2
Aoki KR.
Evidence for antinociceptive activity of botulinum toxin type A in pain management.
Headache
2003; 43 (Suppl. 1): S9–S15.
- 3
Evers S,
Vollmer-Haase J,
Schwaag S,
Rahmann A,
Husstedt IW,
Frese A.
Botulinum toxin A in the prophylactic treatment of migraine – a randomized, double-blind, placebo-controlled trial.
Cephalalgia
2004; 24: 838–43.
